Biovian acquired by Keensight
Acquisition by Keensight Capital
May 2018
Sector: Healthcare
Service: M&A
Our role
Exclusive financial adviser to Keensight Capital on the acquisition of Biovian
Buyer
Keensight Capital is a European growth buyout investor with deep expertise in Technology and Healthcare. For over 20 years, Keensight Capital has leveraged its knowledge in investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of EUR 15 million to EUR 250 million
Target
Biovian is a one-stop-shop Contract Development and manufacturing Organisation (CDmO) of biopharmaceuticals covering GMP services from early development to finished aseptically filled product. Since its establishment in 2003, Biovian has served a steadily growing stream of satisfied customers with Biopharmaceutical manufacturing excellence supported by broad EMA manufacturing authorisation and successful FDA inspection